Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEVE trial of intravesical Xeomin via Vibe System for female idiopathic overactive bladder
2026-526512-36-00Phase 2Authorised
- Sponsor
- Vensica Therapeutics
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in overactive bladder (OAB) comparing NT 201 intravesical administration using Vibe System with Placebo/sham control (2 arms). Primary endpoint: Change from baseline in mean daily urinary incontinence episodes. Planned start Oct 2026; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2026-526512-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526512-36-00.